Related references
Note: Only part of the references are listed.Mantle cell lymphoma: Report of the 2009 Mantle Cell Lymphoma Consortium Workshop
Michael E. Williams et al.
LEUKEMIA & LYMPHOMA (2010)
Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling
Silvia Bea et al.
BLOOD (2009)
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
Mars B. van 't Veer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
E. S. Jaffe
Hematology-American Society of Hematology Education Program (2009)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations
J. Brunet et al.
CLINICAL GENETICS (2008)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network
M Tiemann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Current treatment approaches for mantle-cell lymphoma
TE Witzig
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma
R M'kacher et al.
ONCOGENE (2003)
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma:: a prospective study
F Lefrère et al.
LEUKEMIA (2002)
Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?
I Barista et al.
ANNALS OF ONCOLOGY (2002)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
JM Foran et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)